Evidence map›Paper›PMID 42040803›Full record

ReviewGalen medical journal2022

Multiple Sclerosis Impact on Pregnancy: An Update on Management Issues : Management of MS During Pregnancy.

Ahmadreza Badali, Rahil GhorbaniNia, Shima Mohammadian, Sahar Poudineh, Alireza Sarlak, Mohammadreza Eghbali, Esmaeil Behzadi, Morteza Jafarinia

Abstract readReview
In one paragraph

Review in Galen medical journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ahmadreza BadaliMedical School, Tabriz University of Medical Sciences, Tabriz, Iran.
Rahil GhorbaniNiaFaculty of Management and Medical Information, Kerman University of Medical Sciences, Kerman, Iran.
Shima MohammadianDepartment of Gynecology Oncology, Kamali Teaching Hospital, Alborz University of Medical Sciences, Karaj, Iran.
Sahar PoudinehSchool of Medicine, Mashhad Azad University, Mashhad, Iran.
Alireza SarlakSchool of Medicine, Hamedan University, Hamedan, Iran.
Mohammadreza EghbaliSchool of Medicine, Hamedan University, Hamedan, Iran.
Esmaeil BehzadiSchool of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Morteza JafariniaShiraz Neuroscience Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Women with multiple sclerosis (MS) of reproductive age are becoming pregnant at an alarmingly high rate. Disease control is required during the preconception, prenatal, and postpartum periods to reduce the likelihood of relapses of MS while minimizing hazards to the mother and fetus. It has long been understood that the disease activity of MS noticeably decreases in the third trimester of pregnancy, then noticeably increases in the first three months after delivery before returning to its pre-pregnancy baseline. Relapse during pregnancy and high rates of relapse before becoming pregnant have both been linked to an increased risk of postpartum attacks. In patients with relapse MS, recent results continue to support the notion that pregnancy does not affect long-term disease progression (and may even have the opposite effect); the situation is less clear for patients with progressive MS. It is comforting to know that none of the MS disease-modifying medications have been shown to cause teratogenic consequences. This review discusses the effects of pregnancy on disease activity and how to handle relapses when pregnant and breastfeeding.

Indexed as

Disease-Modifying TreatmentsMultiple SclerosisPregnancyPrimary ProgressiveRelapsing-remitting

Identifiers

PMID42040803
PMCPMC12327984

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.